Ryzolt: US FDA label indications
US FDA labelNot medical advice
The product name above is taken from the label's own indications text; the source record has no brand or generic name field.
Indications and usage (label excerpt)
Indications and Usage RYZOLT™ is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
Warnings (label excerpt)
Warnings Seizure Risk Seizures have been reported in patients receiving tramadol hydrochloride within the recommended dosage range. Spontaneous postmarketing reports indicate that seizure risk is increased with doses above the recommended range. Concomitant use of tramadol hydrochloride increases the seizure risk in patients taking: Selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), Tricyclic antidepressants (TCAs), and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.), or Other opioids. Administration of RYZOLT™ may enhance the seizure risk in patients taking: Monoamine Oxidase (MAO) inhibitors (See also WARNINGS, Use with MAO Inhibitors and Serotonin Re-uptake Inhibitors), Neuroleptics, or Other drugs that reduce the seizure threshold. Risk of convulsions may also be increased in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (such as head trauma, certain metabolic disorders, …
Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).
Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.